|
KCTD18 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6251444634463E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.2854608750531E-14 |
| Normal-vs-Stage2 |
4.38749999998045E-06 |
| Normal-vs-Stage3 |
1.95399252334028E-13 |
| Normal-vs-Stage4 |
1.10029763078501E-11 |
| Stage1-vs-Stage2 |
3.675200E-01 |
| Stage1-vs-Stage3 |
9.351500E-02 |
| Stage1-vs-Stage4 |
1.034230E-01 |
| Stage2-vs-Stage3 |
6.926200E-02 |
| Stage2-vs-Stage4 |
6.305900E-02 |
| Stage3-vs-Stage4 |
7.707600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
2.808600E-04 |
| Normal-vs-Asian |
9.651299981428E-09 |
| Caucasian-vs-AfricanAmerican |
1.472950E-01 |
| Caucasian-vs-Asian |
4.672600E-01 |
| AfricanAmerican-vs-Asian |
4.248200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.12220233106086E-11 |
| Normal-vs-Female |
1.62680979798324E-12 |
| Male-vs-Female |
9.619600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.77624581709779E-12 |
| Normal-vs-Age(41-60Yrs) |
3.49598128224216E-12 |
| Normal-vs-Age(61-80Yrs) |
1.71069824972392E-11 |
| Normal-vs-Age(81-100Yrs) |
2.837600E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.917400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.766200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.128200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.447600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.928600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.084600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.974060E-02 |
| Classical-VS-Follicular |
3.173200E-01 |
| Classical-VS-Other |
3.555600E-01 |
| Classical-VS-Normal |
1.63924429585904E-12 |
| Tall-VS-Follicular |
3.344400E-03 |
| Tall-VS-Other |
7.666600E-01 |
| Tall-VS-Normal |
8.21598344913355E-12 |
| Follicular-VS-Other |
2.874000E-01 |
| Follicular-VS-Normal |
3.8650000000473E-07 |
| Other-VS-Normal |
6.033700E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.6655011531318E-11 |
| Normal-vs-N1 |
1.46549439250521E-13 |
| N0-vs-N1 |
9.203800E-03 |
|
|
